ERBB2 and cholangiocarcinoma: Lapatinib treatment markedly inhibits the growth of CC cells by suppressing EGFR, human epidermal growth factor receptor (HER)2, and AKT activation relative to trastuzumab as an ERBB2 inhibitor [148].